The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialā¦ (NCT02977117) | Clinical Trial Compass
CompletedPhase 2
The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis
Denmark59 participantsStarted 2016-12
Plain-language summary
The purpose of this trial is to examine the effect of increasing dialyse magnesium on serum calcification propensity in subjects with end-stage renal disease treated with haemodialysis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ā„ 18 years.
* Treatment with maintenance haemodialysis for more than 3 months.
* Dialysate magnesium of 0.5 mmol/L (standard concentration).
* Serum magnesium \< 1.2 mmol/L on average of previous measurements within the last 3 months.
* Women of childbearing age must be actively using contraceptive therapy (p-pills, estrogen depots or intrauterine device) as well as have a negative pregnancy test.
* Written informed consent.
Exclusion Criteria:
* Treatment with peritoneal dialysis.
* Parathyroid hormone \> 66 Ļmol/L.
* Previous parathyroidectomy.
* Current treatment with magnesium containing medication or supplements.
* Other diseases or conditions, which, in the opinion of the site investigator, would prevent participation in or completion of the trial.
* Pregnancy or breastfeeding.
What they're measuring
1
Between-group difference in serum calcification propensity at follow-up